Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0026986 (myelodysplastic syndrome)
 14,926 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Among 90,128 patients with malignancies in the years 1976-1989 acute non lymphoblastic leukaemia (ANLL) was diagnosed in 351 patients (0.4%) and in 15 (4.3%) of them ANLL was secondary neoplasm. Secondary ANLL occurred in 10% of all the 148 secondary malignancies observed at that period of time and constituted 6.7% of secondary malignancy in patients with solid tumours and 43% in patients with myeloproliferative syndromes as a first malignant neoplasm. In the treatment of first malignancy radiotherapy was applied in 11 persons, in combination with chemotherapy in 7 of them and chemotherapy alone was given to 4 patients. The appearance of the secondary ANLL was usually preceded by the myelodysplastic syndrome. Morphologically, secondary ANLL belonged mostly to M6 and M4 (8 patients) according to FAB classification. The course of ANLL was fulminant and the disease was completely resistant to the treatment.
Acta Haematol Pol 1992
PMID:[Acute nonlymphoblastic leukemia as a secondary malignancy--demonstration of 15 patients]. 129 9

This paper summarizes results of rhuEPO--treatment obtained by different authors in 27 patients with a myelodysplastic syndrome (MDS). Only 1/3 of all patients with a MDS were responsive to rhuEPO treatment, while in 2/3 of these subjects no amelioration of anaemia was noticed, even after extremely high doses of this hormone. A detailed description of a patient with MDS, which was observed by the authors, is presented. In this patient the anaemia was refractive even after very high doses of rhuEPO administered for 10 weeks.
Pol Arch Med Wewn 1992 Dec
PMID:[Efficacy of recombinant human erythropoietin (rhuEPO) in treatment of anemia in patients with myelodysplastic syndrome]. 130 May 67

In 23 patients with myelodysplasia syndromes cytomorphological examinations of peripheral red blood cells and bone marrow cells were carried out. Apart from anisocytosis and poikilocytosis observed in all patients, the most frequent changes were macrocytosis and megalocytosis or erythrocytes and their precursors, presence of erythroblasts in peripheral blood and disturbances of megakaryopoiesis. None of these changes was characteristic in a given type of these syndromes.
Acta Haematol Pol 1991
PMID:[Morphological changes in peripheral blood and bone marrow in patients with myelodysplastic syndromes]. 182 67

The activity of alkaline phosphatase and peroxidase was measured in polymorphonuclears in 20 cases of myelodysplasia syndromes, 10 cases of chronic myeloid leukaemia. Reduced phosphatase activity was found in 5 cases and peroxidase activity in 3 cases of myelodysplasia syndromes. No evident correlation was noted between the activity of these enzymes and prognosis. Increased proportion of peroxidase-negative granulocytes was observed, moreover, in most cases of chronic myeloid leukaemia. The observations will be continued in larger material.
Acta Haematol Pol 1991
PMID:[Results of selected cytochemical studies of mature granulocytes in myelodysplastic syndromes and various other hematologic diseases]. 182 68

The rate of alloimmunization to red blood cell antigens in 1502 multitransfused patients, mainly with blood disorders, was analyzed in a retrospective study. The overall incidence of alloantibodies was 5.7%. Three groups of patients were identified with different potential for antibody production. The lowest probability (1.8%) of alloimmunization was found in the group of patients with lymphoproliferative syndromes, acute myeloid leukaemia and burn disease. The highest probability (33.4%) of immune response to red blood cell antigens was found in patients with AIHA, liver cirrhosis and myelodysplastic syndrome. In the group of patients with chronic myeloid leukaemia, pancytopenias, anaemias of various origin and aplastic anaemia the probability of alloimmunization ranged from 5.7% to 13.6%. A possible role of genetic-factors and immune competence status in post-transfusion alloimmunization is briefly discussed.
Mater Med Pol
PMID:Analysis of immune response to red blood cell antigens in multitransfused patients with different diseases. 207 55

The paper presented a case of a patient with type III by FAB myelodysplastic syndrome, in whom during a low dose cytarabine therapy ventricular fibrillation occurred. Authors discussed roles of anemia, ischemic heart disease and hypokalemia as factors which could increase circulatory system sensitivity on cytarabine action.
Kardiol Pol 1989
PMID:[Ventricular fibrillation in a patient with myelodysplastic syndrome treated with small doses of cytarabine]. 262 13

Kinetics of thermal decomposition of trihydrate of sodium salt of 1,2,3,4-tetrahydro-2-methyl-1,4-dioxo-2-naphthalenesulfonic acid (MDS, vitamin K3 soluble form) in solid state by accelerated aging method at elevated temperature has been studied. It was found that the process occurs according to Prout-Tompkins model and its rate depends on temperature, humidity and particle size of the substance. Thermodynamic parameters of the reaction (Q10(0), EA, delta H not equal to, delta S not equal to, delta G) were determined and theoretically predicted stability of MDS at room temperature is given. The reaction mechanism assumes a preliminary dehydration occurring via the successive elimination of one and a half, two and a half and finally three molecules of water. The obtained anhydrous form decomposes thermally forming free radical intermediates and yielding finally 2-methyl-1,4-naphthoquinone (vitamin K3), SO2 and NaOH.
Pol J Pharmacol Pharm
PMID:Kinetics of drug decomposition. Part 73. Kinetics and mechanism of vitamin K3 soluble form thermal decomposition in solid phase. 718 50

Granulocyte--colony stimulating factor (G-CSF, filgrastim) is a glycoprotein hormone of the hematopoietin family that primarily influences the proliferation and differentiation of neutrophilic granulocytic precursors. As with all glyco-protein hormones, G-CSF interacts with target cells by binding to specific cell-surface receptors. It stimulates proliferation, differentiation and activation of cells of the neutrophil--granulocyte lineage and has been investigated as therapy for patients with various neutropenic conditions. A major use for recombinant G-CSF therapy will be in ameliorating the neutropenia which follows cytoreductive chemotherapy. The increase in neutrophils produced by this factor render it a useful treatment for conditions such as congenital, acquired and cyclic neutropenias. It may be an effective therapy in myelodysplasia and aplastic anaemia. G-CSF is also useful in accelerating the recovery of transplanted bone marrow in patients with leukaemia, lymphoma and solid tumors. G-CSF is well tolerated. The most frequently reported adverse effect is mild to moderate bone pain.
Acta Haematol Pol 1993
PMID:[Biological properties and clinical application of filgrastim (G-CSF)]. 750 84

Myelodysplastic syndromes (MDS) comprise a heterogenous group of closely related, acquired stem cell disorders. Various patterns of clinical evolution have been observed in patients with different subtypes according to the FAB (French-American-British) criteria. The marked differences in clinical outcome among MDS patients have encouraged us to search the alternative variables for predicting leukemic transformation and survival. During the past 10 years different prognostic scoring systems based on age combined with blood and bone marrow parameters have been described. This has enabled the identification of patients with better and worse prognosis among different MDS types. Additionally, studies of cytogenic patterns in MDS patients and widespread availability of bone marrow histological specimens extended the possibility of prognosis in this disease. Similarly, the in vitro culture results of hematopoietic cells using growth and differentiation factors have given very promising results. The high prevalence of RAS mutation in patients with MDS has been defined, but its clinical usefulness is under discussion.
Acta Haematol Pol 1995
PMID:[Contemporary possibilities of prognosis in myelodysplastic syndromes]. 765 17

Eighty-two patients treated surgically for myelomeningocele or myelodysplasia between 1945 and 1993 are presented. Family and environmental history has been studied. The presence of genetic markers (HLA B27, ABO, Rh) has been investigated. Heterogenicity of localization and type of defect in the series reviewed has been found. Associations between certain genetic features confirm multisite mechanism of closure of the neural tube. The relationship between site of neural tube defect and concurrence of developmental defects has been substantiated. A higher site often results in multiple defects.
Chir Narzadow Ruchu Ortop Pol 1995
PMID:[Clinical heterogeneity of myelomeningocele as evidence of multisite closure of the neural tube]. 767 38


1 2 3 4 Next >>